The activities of promoters and enhancers are generated by the combinatorial effects of the factors which interact with them. The Polyoma virus (Py) enhancer contains sequences that are positively regulated by the proto-oncogene Jun. Suprisingly, Jun has an additional and overriding repressing effect on enhancer activity, which is cell specific. Thus overall enhancer activity cannot be simply deduced from the properties of individual elements. We present evidence that repression is indirect.
INTRODUCTION
The transcription factor complex API mediates the transcriptional response to serum growth factors and the expression of oncogenes through sequences resembling TGAC/GTCA. API consists of dimers formed by the interaction between the leucine repeats of members of the jun, fos and CREB gene families. The transforming proteins v-Jun and v-Fos contain mutations which deregulate API activity. Jun has mainly been studied as a transcriptional activator (reviewed in 1). However, its activity as a repressor may be important since Jun inhibits the fos promoter and possibly the myc promoter (see Discussion). We describe here a negative regulatory activity of v-and c-Jun, resulting in efficient inhibition of the Polyoma virus (Py) enhancer.
Although in recent years there has been considerable progress in understanding how transcription is activated, considerably less is known about how it is inhibited. Several different mechanisms of repression have been described (for reviews see 2 -4). i) One involves competition between factors for binding to overlapping DNA sequences, ii) Another, 'quenching', results from binding of factors to non-overlapping DNA sequences, and protein-protein interactions that inhibit transcription, iii) 'Squelching' is a consequence of sequestration of general transcription factors into inactive complexes by an overexpressed factor. It therefore requires only the activation domain of the transcription factor and not its DNA binding domain nor the cognate DNA motif, iv) Finally, expression of dimer-forming proteins, such as Jun, could generate complexes with cellular factors that are either less efficient activators or bind to inappropriate sequences.
We have found that Jun expression activates the Py enhancer through the Jun (API) binding site (5, 6 , this report). However, in some cell-lines Jun has a supplementary overriding activity, repression of enhancer activity. We show that inhibition is not mediated by either the major or the minor Jun (API) binding sites in the enhancer, and that low levels of Jun, below the optimum for activation, are sufficient. Both the activation and DNA-binding domains of Jun are required. Repression is not prevented by co-expression of c-Fos, a factor that efficiently heterodimerizes with Jun. These results argue against the following mechanisms for the inhibition: competition for binding to overlapping motifs, quenching, squelching, or the formation of inappropriate dimers. They suggests that it results from an indirect mechanism which requires both the DNA-binding and activation properties of Jun.
MATERIALS AND METHODS Reporters
The recombinant p/3DEX (Fig. 1 ) was constructed by inserting the rabbit /3-globin gene Kpnl (-700 to +3320) fragment (7) into the Kpnl site of pEMBL18.2. p/3DEAB contains the SmaI(5267)-HindUI(5O21) fragment from p/3Py/3 (7) between the Smal and HindJH sites of p/3DEX. p/3DE411 and p/3DE426 contain the SmaI(5267)-PvuJJ(5131) fragment from p/3Pyj3 and the PvuII(5130)-XhoI(5090) fragments from either pA411 or pA426 (5) respectively, between the Smal and Xhol sites of P/3DEX. pGlPyA and pGlPyB have either the PvuII(5130)-HindUI(5021) or the XhoI(5267)-PvuII(5131) framents from P/3DEAB in either the Xhol or Hindm sites of pG 1, respectively. The half-site abutted to PvuJJ was repaired with Klenow polymerase. pGlPyA40 and pGlPyA40I were obtained by ligating the BstNI(5227)-HindHJ.(5021) fragment from p/3DEAB with HindUJ linearised pGl, repairing with Klenow and religating. The internal control p/3CBX2 contains two copies of the SV40 enhancer upstream from the conalbumin promoter and j3-globin coding sequences (8) . Other recombinants have been described elsewhere (5,6,8-ll) .
Expression vectors
pShcJ contains the human c-jun cDNA (reconsructed from the EcoRI-Nael and Nael-BamHI fragments from ph-cJ-2 and phcJ-1 respectively, ref.12) between the EcoRI and BamHI sites of pSG5. pGlPy has the XhoI-HindlH fragment from pPy (8) between the Xhol and Hindin sites of pGl. Other recombinants have been described previously.
Cells, transfections, SI nuclease analysis
LMTKr fibroblasts were grown in Dulbecco + 10% foetal calf serum. Subconfluent celJs in 9 cm Petri-dishes were transfected by the DEAE-dextran + chloroquine technique. After 48h total RNA was extracted by the hot phenol method and analysed by quantitative SI nuclease mapping as described previously (11) . The experiments were repeated at the very least two times with two preparations of plasmids.
Whole-cell extracts 48h after transfection the cells were rinsed with PBS, harvested in STE (lOmM TrisHCl pH8.0, lmM EDTA, 150mM NaCl), resuspended in TGKD (lOmM TrisHCl pH8.0, 0.6M KC1, 0.5 mM DTT, 10% glycerol), lysed with three cycles of freeze-thaw and centrifuged at 10 4 g for 20 min at 4°C. The supernatant was aliquoted and the concentration of proteins was measured using the BCA* Protein Assay Reagent (Pierce).
Protein blots
Proteins (40 /ig) were separated on 12% SDS-polyacrylamide gels, and electrophoretically transfered to PVDF membranes using a Hoefer transphor apparatus for 3h at 100V and 4°C. The membranes were probed with rabbit anti-lex A serum (kindly provided by C. Besmond and J.Kamens), alkaline phosphatase conjugated donkey anti-rabbit IgG (Jackson Immunoresearch Laboratories) and BCIP and NBT (Bio-Rad).
RESULTS
The Py enhancer is efficiently inhibited by v-jun expression in LMTK-cells Py enhancer activity in LMTK" fibroblasts was studied using short term transfection assays. Specific RNA transcribed from the reporters (see Fig. 1 Repression was observed at all the concentrations of expression vector tested (lanes 1~8, Fig. 2 ). It was specific to the Py enhancer because v-Jun did not inhibit either pG 1 based reporters containing active TCII and KBI motif multimers (data not shown) or the internal control, which contains the SV40 enhancer and Figure 1 . Structure of reporter recombinants. pGl contains rabbit 0 globin gene sequences from -109 to + 1600. Derived recombinants contain Py enhancer inserts upstream from the promoter: pGlPy, the complete enhancer from 5021 to 5267; pGlPyA40 and pGlPyA401, the deleted enhancer from 5021 to 5227 in the indicated orientations; pGIPyA, the A fragment from 5130 to 5021; pGlPyB, the B fragment from 5267 to 5131; pGlP4, a head to tail multimer of the alpha domain from 5108 to 5130. P0DEX contains the /3 globin gene from -700 to +3320 in pEMBL18.2. Derived recombinants contain downstream Py enhancer inserts: p/3DEAB, the complete enhancer from 5021 to 5267; p0DE411, a deleted enhancer from 5090 to 5267; p0DE426, the 5090 to 5267 fragment with a triple base-pair mutation in the API site which prevents API binding. p0Py|3 contains the Py enhancer in the reporter p/?(x2 the conalbumin promoter (see CON band in Fig. 2) . In contrast, a reporter containing four copies of the API (v-jun) binding-site of the Py enhancer was activated by v-jun expression. Increasing the amount of expression vector augmented stimulation (pGlP4, lanes 9-12, Fig. 2 ). The enhancer was efficiently inhibited with sub-optimum levels of v-jun for activation, strongly suggesting that repression does not result from titration of general transcription factors or co-activators (squelching). Inhibition is also cell specific since in F9 EC cells v-jun stimulates the inactive Py enhancer (5).
Sequences of the Py enhancer required for represssion
v-Jun may inhibit the Py enhancer through the API (v-jun) binding site, even though it stimulates the P4 multimer, because of the effects of surrounding Py enhancer sequences. To investigate this possibility, we used three reporters: p/3DEAB with the Py enhancer downstream from the globin gene, p0DE411with a deletion in the A fragment, and pj3DE426 with an additional triple base-pair mutation in the API motif that prevents API binding (6) . v-Jun expression inhibited the Py enhancer in p/3DEAB Ganesl-3, Fig. 3A) , showing that a distantly located enhancer can also be inhibited. Using other reporters, we have confirmed that repression does not depend on the distance of the enhancer from the promoter (results not shown). Deleting part of the A fragment decreased enhancer activity, but does not prevent v-Jun repression (lanes 4-6, Fig.  3A ). Mutating the v-Jun (API) binding site further decreased enhancer activity (lanes 1 and 7), showing that a positively acting factor binds to this site. However, v-Jun still repressed to a similar extent (lanes 7-9). The Py enhancer contains another motif with lower affinity for API (13) . Deletion of a 40 base-pair fragment encompassing this site (pGlPyA40 and pGlPyA40I, Fig. 1 ) did not prevent v-jun inhibition (lanes 1,2,4,5,7,8, Fig 3B) . These results show that neither the major API binding site nor a secondary site are required for repression of enhancer activity. Interestingly, both the A and the B subfragments of the enhancer were repressed by v-jun (lanes 1-4, Fig. 3C and Fig. 1 ), suggesting that there are several separable sequences that mediate repression. 
Sequences of v-jun required for repression
Deletion mutants of v-jun were constructed to study the role of different domains of the factor in repression. They were expressed as fusion proteins with the DNA binding domain of the bacterial repressor lex-A (see Fig.4Q to measure activation through the heterologous DNA binding domain and to facilitate detection of the protein in transfected cells using anti-lex-A antibodies. The wild-type fusion protein efficiently repressed the enhancer (see Fig. 4A ). Progressive deletion of the activation domain of v-Jun decreased in parallel both repression of the enhancer and activation through either the P4 multimer (Fig. 4A) or the lex-A operator (results not shown). The deletions did not affect the amount of v-jun expressed in the cell (see Fig. 4B ).We also investigated whether DNA binding was required for repression. not shown). These data show that both the activation and the DNA binding domains of v-Jun are required for repression, and they strongly suggest that its full activity as a transcription factor is necessary.
Repression does not result from titration of a limiting quantity of c-fos
v-jun expression in the cell may generate dimers with endogenous factors. v-Jun dimerises through its leucine repeat with members of the jun and fos gene famiies and with several members of the CREB gene family. As shown in Figure 5 , we found that c-Jun expression inhibited the enhancer. This suggests that v-Jun does not repress by titrating endogenous c-Jun. These results also show that the sequence differences between c-and v-Jun are not essential for repression. c-Fos expression also repressed Py enhancer activity, but to a lesser extent than Jun (Fig. 5) . If repression by exogenous Jun and Fos results from dimer formation with endogenous proteins, then repression should be prevented by co-expression of both factors. However, we have never observed decreased repression by co-expression of Fos and Jun (see Fig 5 and data not shown) . These results, together with the inability of the v-jun deletion that retains the leucine repeat to repress (see LA9 above and Discussion), suggest that titration of a limiting factor is not the mechanism of repression. There is no cooperativity between Fos and Jun for either repression of the enhancer or activation of pGlP4, under the conditions used (unpublished results). In this respect repression and activation have similar properties.
DISCUSSION

The mechanism of Py enhancer repression by Jun
We have found that Jun represses the Py enhancer in a cell specific manner; it inhibits the enhancer in LMTK" fibroblasts and stimulates it in F9 EC cells (this report; 5). This difference apparently does not stem from the greater activity of the enhancer in fibroblasts, because it can still be repressed when its activity is decreased (in low serum, results not shown).
Various mechanisms have been described by which factors inhibit transcription (reviewed in 2-4). Several require that the factors bind to their cognate motifs. A classical mechanism is competition between proteins for binding to overlapping sites. For example, API represses transcription of the osteocalcin gene by binding to sequences overlapping the response elements of the vitamin D3 and retinoic acid receptors (14) . A second mechanism, quenching, involves protein-protein interactions between activators and repressors that bind to non-overlapping DNA sequences. Neither of these mechanisms can explain Py enhancer repression since mutating the Jun binding sites (API motifs) does not decrease repression. Rather than mediating repression, the API motifs are positively acting elements, since mutating them decreases enhancer activity, and furthermore the isolated multimerized motif is activated by Jun expression. Another arguement against competition for binding is that Nterminal deletion mutants of Jun that can still bind DNA do not inhibit. Repression is particularly powerful since it overrides the positive effects of Jun. There could be multiple cell specific targets for inhibition since the A and B enhancer fragments are independently repressed. These targets are not found in the SV40 enhancer, which is not down regulated by Jun.
Other mechanisms do not require DNA binding by the repressor. Squelching results from sequestration of co-activators or general transcription factors by over-expression of an activator (15, 16) . The activation domain of the overexpressed protein is sufficient for squelching. It can not account for repression of the Py enhancer, i) Low levels of Jun are sufficient, below the optimum for stimulation through the AP-1 motif, ii) The activation domain alone does not repress, iii) Promoter activity in the absence of the enhancer is not significantly affected.
Jun could form inactive dimers with cellular proteins. Jun can dimerize with itself, with all the jun and fos gene-family members, and with at least two of the CREB proteins (17) . The Jun/CREB2 heterodimer is inactive (18) . Jun-B expression has been shown to inhibit c-Jun (19, 20) , perhaps by forming relatively inactive dimers. This mechanism cannot account for our observations. N-terminal deletion mutants of Jun that are competent for dimer formation do not repress. Furthermore, coexpression of c-Fos, that can efficiently dimerize with c-Jun and form active complexes, does not prevent inhibition.
Our results are most compatible with an indirect mechanism of repression. One possibility is that Jun affects the synthesis of modulators of Py enhancer activity, by controlling transcription of their genes through AP-1 sites in their promoters. This would in particular explain why mutating Jun proportionally decreases repression and activation. Further work will be required to substantiate or refute this model.
How does Jun repress other promoters?
One of the best studied examples of transcriptional repression is inhibition of the c-fos promoter by Jun and Fos. Repression is not mediated by the AP-1 motif, but by the CArG box which binds the factor p67-SRF (21 -25). Gius et. al. (25) found that the conserved C-terminus of Fos mediates repression. In contrast, Lucibello et. al. (22) found that the leucine repeat is necessary. c-Jun inhibits on its own and enhances inhibition by Fos (21, 22) . Strangely, unlike Fos, Jun does not down regulate the CArG box of the Erg-1 promoter (25), suggesting that there are different mechanisms for these similar sequences. The mechanisms are not known, but again appear to be indirect since Fos and Jun do not bind directly to the CArG box, and do not form complexes with p67-SRF. The mechanisms may involve post-translational modification of p67-SRF or effects on proteins that interact with p67-SRF.
c-Jun and c-Fos modulate the glucocorticoid response of the proliferin promoter. The response element binds c-Fos, c-Jun and the glucocorticoid receptor. c-Jun and the receptor are required to obtain a positive glucocorticoid effect, and the addition of c-Fos generates a negative glucocorticoid effect. The receptor interacts with c-Jun in vitro, suggesting that protein-protein interactions help select between positive and negative regulation from a single DNA element (26) . Myc plays an important role in cellular proliferation. c-Jun and c-Fos bind to a negative element of the myc promoter suggesting that they negatively regulate its activity (27, 28) .
Repression of the Py enhancer does not obviously resemble any of these examples of inhibition by Jun and Fos. Elucidation of the mechanisms by which these proto-oncogenes repress as well as stimulate transcription, should help in understanding how they transform cells
